Resveratrol ameliorates depressive disorder through the NETRIN1-mediated extracellular signal-regulated kinase/cAMP signal transduction pathway

Wang,Feifei; Wang,Jinhui; An,Jinghong; Yuan,Guoming; Hao,Xiaolei; Zhang,Yi

doi:10.3892/mmr.2018.8379

Resveratrol ameliorates depressive disorder through the NETRIN1-mediated extracellular signal-regulated kinase/cAMP signal transduction pathway

Authors:
- Feifei Wang
- Jinhui Wang
- Jinghong An
- Guoming Yuan
- Xiaolei Hao
- Yi Zhang
View Affiliations

Affiliations: Clinical Laboratory, The First Hospital of Harbin, Harbin, Heilongjiang 150000, P.R. China, Department of Psychiatry and Psychology, The First Hospital of Harbin, Harbin, Heilongjiang 150000, P.R. China
Published online on: January 5, 2018 https://doi.org/10.3892/mmr.2018.8379
Pages: 4611-4618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Depressive disorder is a mental health disorder caused by the dysfunction of nerve regeneration, neuroendocrine and neurobiochemistry, which frequently results in cognitive impairments and disorder. Evidence has shown that resveratrol offers benefits for the treatment of depressive disorder. In the present study, the therapeutic effects of resveratrol were investigated and the potential mechanisms mediated by resveratrol were analyzed in hippocampal neuron cells. The anti‑oxidative stress and anti‑inflammatory properties of resveratrol were also examined in vitro and in vivo. The results revealed that resveratrol administration inhibited the inflammation in hippocampal neuron cells induced by ouabain. Oxidative stress in the hippocampal neuron cells was ameliorated by resveratrol treatment in vitro and in vivo. In addition, the apoptosis of hippocampal neuron cells was inhibited by the upregulation of anti‑apoptotic genes, including P53, B‑cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated death promoter, and the downregulation of the cleaved caspase‑3 and caspase‑9. The analysis of the mechanism revealed that that resveratrol treatment suppressed the apoptosis of hippocampal neuron cells through the NETRIN1‑mediated extracellular signal‑regulated kinase/cAMP signal transduction pathway. The results of the in vivo assay showed that resveratrol treatment led to improvements in cognitive competence, learning memory ability and anxiety in a mouse model of depressive disorder induced by ouabain. In conclusion, these results indicated that resveratrol treatment had protective effects against oxidative stress and neuroinflammatory pathogenesis through the NETRIN1‑mediated extracellular signal‑regulated kinase/cAMP signal transduction pathway, suggesting that resveratrol treatment may be a potential antidepressant agent for the treatment of depressive disorder.

View Figures

View References

1	Kato M and Serretti A: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 15:473–500. 2010. View Article : Google Scholar : PubMed/NCBI
2	Whale R, Terao T, Cowen P, Freemantle N and Geddes J: Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 24:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
3	Andrade P, Noblesse LH, Temel Y, Ackermans L, Lim LW, Steinbusch HWM and Vandewalle VV: Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review. Acta Neurochir (Wien). 152:565–577. 2010. View Article : Google Scholar : PubMed/NCBI
4	Carnevale T: An integrative review of adolescent depression screening instruments: applicability for use by school nurses. J Child Adolesc Psychiatr Nurs. 24:51–57. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rayner L, Price A, Evans A, Valsraj K, Hotopf M and Higginson IJ: Antidepressants for the treatment of depression in palliative care: Systematic review and meta-analysis. Palliat Med. 25:36–51. 2011. View Article : Google Scholar : PubMed/NCBI
6	Evans S: Review: Mindfulness-based therapies effective for anxiety and depression. Evid Based Ment Health. 13:1162010. View Article : Google Scholar : PubMed/NCBI
7	Garnock-Jones KP and McCormack PL: Escitalopram: A review of its use in the management of major depressive disorder in adults. CNS drugs. 24:769–796. 2010. View Article : Google Scholar : PubMed/NCBI
8	Croxtall JD and Scott LJ: Olanzapine/fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder. CNS drugs. 24:245–262. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sharpley CF: A review of the neurobiological effects of psychotherapy for depression. Psychotherapy (Chic). 47:603–615. 2010. View Article : Google Scholar : PubMed/NCBI
10	Foland-Ross LC, Hardin MG and Gotlib IH: Neurobiological markers of familial risk for depression. Curr Top Behav Neurosci. 14:181–206. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sorokina ND, Selitskii GV and Kositsyn NS: Neurobiological approach to brain functional asymmetry in depression. Usp Fiziol Nauk. 36:84–93. 2005.(In Russian). PubMed/NCBI
12	Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q and Mi M: Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 47:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ma T, Tan MS, Yu JT and Tan L: Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int. 2014:3505162014. View Article : Google Scholar : PubMed/NCBI
14	O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, O'Farrelly C and Malone KM: Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 30:307–314. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chekalina NI, Kazakov YM, Mamontova TV, Vesnina LE and Kaidashev IP: Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor alpha in patients with coronary artery disease. Wiad Lek. 69:475–479. 2016.
16	Saldanha JF, Leal VO, Rizzetto F, Grimmer GH, Ribeiro-Alves M, Daleprane JB, Carraro-Eduardo JC and Mafra D: Effects of resveratrol supplementation in Nrf2 and NF-kappaB expressions in nondialyzed chronic kidney disease patients: A randomized, double-blind, placebo-controlled, crossover clinical trial. J Ren Nutr. 26:401–406. 2016. View Article : Google Scholar : PubMed/NCBI
17	Rodrigues R, Petersen RB and Perry G: Parallels between major depressive disorder and Alzheimer's disease: Role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol. 34:925–949. 2014. View Article : Google Scholar : PubMed/NCBI
18	Maurya PK, Noto C, Rizzo LB, Rios AC, Nunes SO, Barbosa DS, Sethi S, Zeni M, Mansur RB, Maes M and Brietzke E: The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 65:134–144. 2016. View Article : Google Scholar : PubMed/NCBI
19	Park JS, Kim S, Han DK, Lee JY and Ghil SH: Isolation of neural precursor cells from skeletal muscle tissues and their differentiation into neuron-like cells. Exp Mol Med. 39:483–490. 2007. View Article : Google Scholar : PubMed/NCBI
20	Naganuma Y, Ichii O, Otsuka S, Hashimoto Y and Kon Y: Analysis of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells associated with cardiac myogenesis in mouse embryo. J Vet Med Sci. 75:283–290. 2013. View Article : Google Scholar : PubMed/NCBI
21	Castillo F, Francis L, Wylie-Rosett J and Isasi CR: Depressive symptoms are associated with excess weight and unhealthier lifestyle behaviors in urban adolescents. Child Obes. 10:400–407. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zatzick D, Russo J, Lord SP, Varley C, Wang J, Berliner L, Jurkovich G, Whiteside LK, O'Connor S and Rivara FP: Collaborative care intervention targeting violence risk behaviors, substance use, and posttraumatic stress and depressive symptoms in injured adolescents: A randomized clinical trial. JAMA pediatrics. 168:532–539. 2014. View Article : Google Scholar : PubMed/NCBI
23	Galecki P, Szemraj J, Bienkiewicz M, Zboralski K and Galecka E: Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol. 24:277–286. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS and Harvey PD: Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: Post-hoc analysis of a phase III study. Int Clin Psychopharmacol. 32:72–79. 2017. View Article : Google Scholar : PubMed/NCBI
25	Riepe MW, Gritzmann P and Brieden A: Preferences of psychiatric practitioners for core symptoms of major depressive disorder: A hidden conjoint analysis. Int J Methods Psychiatr Res. 26:2017. View Article : Google Scholar : PubMed/NCBI
26	Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R and Mischoulon D: Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: A proof-of-concept study. Mol Psychiatry. 21:71–79. 2016. View Article : Google Scholar : PubMed/NCBI
27	Miguel-Hidalgo JJ, Whittom A, Villarreal A, Soni M, Meshram A, Pickett JC, Rajkowska G and Stockmeier CA: Apoptosis-related proteins and proliferation markers in the orbitofrontal cortex in major depressive disorder. J Affect Disord. 158:62–70. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ali SH, Madhana RM, K V A, Kasala ER, Bodduluru LN, Pitta S, Mahareddy JR and Lahkar M: Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice. Steroids. 101:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
29	Remus JL and Dantzer R: Inflammation models of depression in rodents: Relevance to psychotropic drug discovery. Int J Neuropsychopharmacol. 19:2016. View Article : Google Scholar : PubMed/NCBI
30	Kandasamy R, Calsbeek JJ and Morgan MM: Analysis of inflammation-induced depression of home cage wheel running in rats reveals the difference between opioid antinociception and restoration of function. Behav Brain Res. 317:502–507. 2017. View Article : Google Scholar : PubMed/NCBI
31	Kohler O, Krogh J, Mors O and Benros ME: Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 14:732–742. 2016. View Article : Google Scholar : PubMed/NCBI
32	Jeong SI, Shin JA, Cho S, Kim HW, Lee JY, Kang JL and Park EM: Resveratrol attenuates peripheral and brain inflammation and reduces ischemic brain injury in aged female mice. Neurobiol Aging. 44:74–84. 2016. View Article : Google Scholar : PubMed/NCBI
33	Vasamsetti SB, Karnewar S, Gopoju R, Gollavilli PN, Narra SR, Kumar JM and Kotamraju S: Resveratrol attenuates monocyte-to-macrophage differentiation and associated inflammation via modulation of intracellular GSH homeostasis: Relevance in atherosclerosis. Free Radic Biol Med. 96:392–405. 2016. View Article : Google Scholar : PubMed/NCBI
34	Maes M, Galecki P, Chang YS and Berk M: A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 35:676–692. 2011. View Article : Google Scholar : PubMed/NCBI
35	Vargas HO, Nunes SO, de Castro MR, Vargas MM, Barbosa DS, Bortolasci CC, Venugopal K, Dodd S and Berk M: Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci Lett. 544:136–140. 2013. View Article : Google Scholar : PubMed/NCBI
36	Mathieu L, Costa AL, Le Bachelier C, Slama A, Lebre AS, Taylor RW, Bastin J and Djouadi F: Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: Involvement of SIRT3. Free Radic Biol Med. 96:190–198. 2016. View Article : Google Scholar : PubMed/NCBI
37	Zepeda N, Solano S, Copitin N, Chávez JL, Fernández AM, García F, Tato P and Molinari JL: Apoptosis of mouse hippocampal cells induced by Taenia crassiceps metacestode factor. J Helminthol. 91:215–221. 2017. View Article : Google Scholar : PubMed/NCBI
38	Hsiao CJ, Lin CL, Lin TY, Wang SE and Wu CH: Imidacloprid toxicity impairs spatial memory of echolocation bats through neural apoptosis in hippocampal CA1 and medial entorhinal cortex areas. Neuroreport. 27:462–468. 2016. View Article : Google Scholar : PubMed/NCBI
39	Banerjee B, Nandi P, Chakraborty S, Raha S, Sen PC and Jana K: Resveratrol ameliorates benzo(a)pyrene-induced testicular dysfunction and apoptosis: Involvement of p38 MAPK/ATF2/iNOS signaling. J Nutr Biochem. 34:17–29. 2016. View Article : Google Scholar : PubMed/NCBI
40	Moriya J, Chen R, Yamakawa J, Sasaki K, Ishigaki Y and Takahashi T: Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. Biol Pharm Bull. 34:354–359. 2011. View Article : Google Scholar : PubMed/NCBI
41	Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther. 8:1183–1190. 2009. View Article : Google Scholar : PubMed/NCBI
42	Naderi EH, Findley HW, Ruud E, Blomhoff HK and Naderi S: Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood. 114:608–618. 2009. View Article : Google Scholar : PubMed/NCBI